A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure
A study for adults with liver disease using study drug Avatrombopag for treatment prior to an elective procedure
Sponsor: Eisai Medical Research Inc.
Enrolling: Male and Female Patients
Study Length: 52 Days
IRB Number: AAAN2203
U.S. Govt. ID: NCT01972529
Contact: Carl Bazil: 212-305-0457 / cwb11@columbia.edu
Additional Study Information: The main purpose of this research study is to investigate the effectiveness of avatrombopag (the study drug under investigation) in increasing the amount of platelets (a type of cell found in the blood) in patients with chronic liver disease who need to have an elective procedure but have thrombocytopenia (low platelet counts) related to the chronic liver disease. This study will look if avatrombopag has the ability to increase your platelet count high enough for you to have an elective procedure and lower theneed for procedure-related platelet transfusions.
This study is closed
Investigator
Carl Bazil, MD, PhD
Do You Qualify?
Do you have any history of arterial or venous thrombosis, including partial or complete thrombosis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Carl Bazil
cwb11@columbia.edu
212-305-0457
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE